ClinicalTrials.gg
CompletedNCT00690794Updated Jul 24, 2012Results posted

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-24.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
726
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
2nd of 45
726 · median 135
Started
2008
with 7 others
Phase 3
16 of 46
none open now
Registered
16th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 2nd largest by enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2008, is one of 16 in phase 3, and was the 16th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older.
  • Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as specified in protocol.
  • Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.
  • Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least one continuous month prior to Visit 1.
  • Willing and able to discontinue use of any topical ocular medication other than the study medication for the duration of the study, including artificial tears.
  • Best corrected visual acuity of -0.6 logarithm of the Minimum Angle of Resolution (logMAR) or better in each eye.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Any medical condition (systemic or ophthalmic) that may preclude safe administration of the test article.
  • Use of contact lenses within 30 days of Visit 1.
  • Use of contact lenses during the study.
  • Participation in an drug or device study within 30 days of entering this study.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
726 participants (actual)

Study arms

  • Experimental
    Travoprost

    One drop self-administered in the study eye(s) once daily for 90 days

    Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

  • Active comparator
    Latanoprost

    One drop self-administered in the study eye(s) once daily for 90 days

    Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)

Interventions

  • DrugTravoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

    Drug page: Travoprost

    Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.

    Also known as: TRAVATAN Z®

  • Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.

    Also known as: XALATAN®

06

What researchers measure

Primary outcomes

  1. Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

    The OSDI is a 12-question validated questionnaire (resultant overall 0-100 point score) used to measure ocular symptoms, visual function and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 90-day OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.

    Time frame: Baseline, Day 90

Secondary outcomes

  1. Percentage of Patients With Corneal Fluorescein Staining Score = 0

    The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (\>50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by the total number of patients analyzed.

    Time frame: Day 90

07

Results

Posted Jul 3, 2012
Limitations and caveats
The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)

Participant flow

Patients were recruited from 70 US study centers. Eligible patients having a diagnosis of open-angle glaucoma or ocular hypertension and on XALATAN® monotherapy for at least one month immediately prior to Visit 1 were enrolled.

Participant flow — Overall Study
MilestoneTravoprostLatanoprost
Started363363
Completed342328
Not completed2135
Withdrew: Adverse event1210
Withdrew: Lost to follow-up14
Withdrew: Withdrawal by subject09
Withdrew: Protocol violation67
Withdrew: Noncompliance12
Withdrew: Other not specified13

Outcome measures

PrimaryMean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

The OSDI is a 12-question validated questionnaire (resultant overall 0-100 point score) used to measure ocular symptoms, visual function and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 90-day OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.

Time frame:
Baseline, Day 90
Reported as:
Mean · Units on a scale
Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
Units on a scaleTravoprostLatanoprost
Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score-11.3 ± 0.9-11.4 ± 1.0
SecondaryPercentage of Patients With Corneal Fluorescein Staining Score = 0

The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (\>50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by the total number of patients analyzed.

Time frame:
Day 90
Reported as:
Number · percentage of patients
Percentage of Patients With Corneal Fluorescein Staining Score = 0
percentage of patientsTravoprostLatanoprost
Percentage of Patients With Corneal Fluorescein Staining Score = 037.140.0

Adverse events

Collected over Adverse events were collected for the duration of the study: 03 July 2008 to 26 May 2009.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost—5/363 (1.4%)0/363 (0%)
Latanoprost—7/363 (1.9%)0/363 (0%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventTravoprostLatanoprost
Abdominal PainGastrointestinal disorders0/3632/363
Coronary Artery OcclusionCardiac disorders1/3630/363
Gastroesophageal Reflux DiseaseGastrointestinal disorders1/3630/363
HyponatraemiaMetabolism and nutrition disorders1/3630/363
Back painMusculoskeletal and connective tissue disorders1/3630/363
ConvulsionNervous system disorders1/3630/363
Atrial FibrillationCardiac disorders0/3631/363
BrachycardiaCardiac disorders0/3631/363
Coronary Artery DiseaseCardiac disorders0/3631/363
Intestinal ObstructionGastrointestinal disorders0/3631/363

Baseline characteristics

Age Continuous
Age Continuous(years)TravoprostLatanoprostTotal
Mean67.1 ± 11.067.8 ± 10.867.5 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)TravoprostLatanoprostTotal
Female211230441
Male132105237
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2008
First posted
Jun 5, 2008
Start
Jul 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jul 3, 2012
Last update
Jul 24, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00690794
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jun 5, 2008
Start date
Jul 2008
Primary completion
May 2009
Completion
May 2009
Results posted
Jul 3, 2012
Last update
Jul 24, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion